110 related articles for article (PubMed ID: 1717384)
1. TRA-1-60: a new serum marker in patients with germ-cell tumors.
Marrink J; Andrews PW; van Brummen PJ; de Jong HJ; Sleijfer DT; Schraffordt Koops H; Oosterhuis JW
Int J Cancer; 1991 Sep; 49(3):368-72. PubMed ID: 1717384
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Int J Androl; 1998 Oct; 21(5):283-8. PubMed ID: 9805244
[TBL] [Abstract][Full Text] [Related]
4. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
5. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan.
Badcock G; Pigott C; Goepel J; Andrews PW
Cancer Res; 1999 Sep; 59(18):4715-9. PubMed ID: 10493530
[TBL] [Abstract][Full Text] [Related]
6. HLA-antigen distribution in seminoma, HCG-positive seminoma and non-seminomatous tumours of the testis.
Kratzik C; Aiginger P; Kuzmits R; Spona J; Kirnbauer M; Seiser A; Mayr WR
Urol Res; 1989; 17(6):377-80. PubMed ID: 2560279
[TBL] [Abstract][Full Text] [Related]
7. Profiles of epitope-defined markers in sera from patients with testicular germ cell tumors.
Yamamoto H; Rudén U; Esposti P; Hirano K; Stigbrand T; Andersson L; Hisazumi H; Wahren B
Urol Res; 1988; 16(1):31-6. PubMed ID: 2449757
[TBL] [Abstract][Full Text] [Related]
8. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary.
Altaras MM; Goldberg GL; Levin W; Darge L; Bloch B; Smith JA
Gynecol Oncol; 1986 Oct; 25(2):150-9. PubMed ID: 2428701
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of alpha-fetoprotein, human chorionic gonadotropin and carcinoembryonic antigen in patients with primary intracranial germ cell tumors.
Arita N; Ushio Y; Hayakawa T; Uozumi T; Watanabe M; Mori T; Mogami H
Oncodev Biol Med; 1980; 1(4-5):235-40. PubMed ID: 6169060
[TBL] [Abstract][Full Text] [Related]
10. Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Richie JP
J Urol; 2014 Mar; 191(3):659. PubMed ID: 24522037
[No Abstract] [Full Text] [Related]
11. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors.
Kamoto T; Satomura S; Yoshiki T; Okada Y; Henmi F; Nishiyama H; Kobayashi T; Terai A; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2002 Nov; 32(11):472-6. PubMed ID: 12499420
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT.
Damjanov I; Horvat B; Gibas Z
Lab Invest; 1993 Feb; 68(2):220-32. PubMed ID: 7680083
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
14. [Use of radioimmunoanalysis for tumor markers in the diagnosis of carcinoma of the testes and prostate].
Kausitz J
Bratisl Lek Listy; 1988 Oct; 89(10):715-24. PubMed ID: 2463063
[No Abstract] [Full Text] [Related]
15. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
17. Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer.
Javadpour N; McIntire KR; Waldmann TA
Natl Cancer Inst Monogr; 1978 Dec; (49):209-13. PubMed ID: 86162
[TBL] [Abstract][Full Text] [Related]
18. Contributions of immunocytochemistry to the diagnosis and study of ovarian neoplasms.
Kurman RJ; Ganjei P; Nadji M
Int J Gynecol Pathol; 1984; 3(1):3-26. PubMed ID: 6203854
[No Abstract] [Full Text] [Related]
19. Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity.
Kawai K; Kojima T; Miyanaga N; Hattori K; Hinotsu S; Shimazui T; Akaza H
Int J Urol; 2005 Mar; 12(3):284-9. PubMed ID: 15828957
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of patients with non-seminomatous germ cell tumors of the testis by determination of alpha-fetoprotein and beta-human chorionic gonadotropin levels and by computed tomography.
Kausitz J; Ondrus D; Belan V; Matoska J
Neoplasma; 1992; 39(6):357-61. PubMed ID: 1283444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
